Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
BREAKDOWN OF THE BLOOD-BRAIN BARRIER PRECEDES SYMPTOMS AND OTHER MRI SIGNS OF NEW LESIONS IN MULTIPLE SCLEROSIS
1990470 citationsAllan G. Kermode, Alan J. Thompson et al.profile →
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
2014304 citationsJeremy Chataway, Nadine Schuerer et al.The Lancetprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by David MacManus
Since
Specialization
Citations
This map shows the geographic impact of David MacManus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David MacManus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David MacManus more than expected).
This network shows the impact of papers produced by David MacManus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David MacManus. The network helps show where David MacManus may publish in the future.
Co-authorship network of co-authors of David MacManus
This figure shows the co-authorship network connecting the top 25 collaborators of David MacManus.
A scholar is included among the top collaborators of David MacManus based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with David MacManus. David MacManus is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Marta, Mónica, David MacManus, Tarek Yousry, et al.. (2016). Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results. Multiple Sclerosis Journal. 21.2 indexed citations
8.
Chataway, Jeremy, Nadine Schuerer, Ali Alsanousi, et al.. (2014). Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. The Lancet. 383(9936). 2213–2221.304 indexed citations breakdown →
9.
Havrdová, Eva, D. H. Miller, J. Theodore Phillips, et al.. (2012). Clinical and neuroimaging outcomes with BG-12 treatment in CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis), a multicenter, randomized, placebo-controlled, phase-3 study. UCL Discovery (University College London).2 indexed citations
10.
Miller, D. H., J. Theodore Phillips, Michael Hutchinson, et al.. (2012). Effects of BG-12 on magnetic resonance imaging outcomes in CONFIRM (Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis), a randomized, placebo-controlled, phase 3 study. UCL Discovery (University College London).3 indexed citations
11.
MacManus, David, D L Miller, Ludwig Kappos, et al.. (2008). The effect of BG00012 on conversion of gadolinium-enhancing lesions to T1-hypointense lesions. UCL Discovery (University College London).2 indexed citations
Rudick, R. A., et al.. (2007). The kinetics of brain atrophy during the first year of treatment with natalizumab. UCL Discovery (University College London).1 indexed citations
14.
Kappos, Ludwig, D. H. Miller, David MacManus, et al.. (2006). BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. UCL Discovery (University College London).11 indexed citations
Page, RA, et al.. (2001). Magnetic resonance spectroscopy of patients with Wilson's disease. UCL Discovery (University College London).1 indexed citations
Molyneux, P. D., Niall Tubridy, Geoff J.M. Parker, et al.. (1998). The effect of section thickness on magnetic resonance lesion detection and quantification in multiple sclerosis. American Journal of Neuroradiology.5 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.